Search

Your search keyword '"Kelley, Michael J"' showing total 947 results
Start Over Author "Kelley, Michael J"
947 results on '"Kelley, Michael J"'

203. Lung cancer management in 2010

Author

Ganti, Apar Kishor, Huang, Chao H., Klein, Mark A., Keefe, Sean, and Kelley, Michael J.

Subjects
Oncology, Experimental, Tumors -- Development and progression, Chemotherapy, Cancer -- Chemotherapy -- Research, Company business management, Health, International Association for the Study of Lung Cancer -- Management
Abstract

The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer., Exciting advances in understanding the biology of lung cancer have occurred over the last few years. These biological advances, coupled with the availability of newer agents and newer surgical techniques [...]

Published
2011

204. Overview of genetic and molecular events in the pathogenesis of lung cancer

Author

Johnson, Bruce E. and Kelley, Michael J.

Subjects
Lung diseases -- Genetic aspects -- Development and progression, Molecular biology -- Genetic aspects, Lung cancer -- Development and progression -- Genetic aspects, Cancer -- Development and progression -- Genetic aspects, Health, Development and progression, Genetic aspects
Abstract

Research on dominant oncogenes and tumor suppressor genes has characterized differences in genetic lesions between small-cell lung cancer (SCLC) and non--small-cell lung cancer (NSCLC) and identified associations with clinical parameters. [...]

Published
1993

210. Abstract 2037: A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)

Author

Patel, Jai N., primary, Jiang, Chen, additional, Owzar, Kouros, additional, Hertz, Daniel L., additional, Mulkey, Flora A., additional, Kelly, William K., additional, Halabi, Susan, additional, Furukawa, Yoichi, additional, Lassiter, Cameron, additional, Dorsey, Susan G., additional, Friedman, Paula N., additional, Small, Eric J., additional, Carducci, Michael A., additional, Mahoney, John F., additional, Kelley, Michael J., additional, Nakamura, Yusuke, additional, Kubo, Michiaki, additional, Ratain, Mark J., additional, Morris, Michael J., additional, and McLeod, Howard L., additional

Published
2016
Full Text
View/download PDF

216. Cancer Incidence among Patients of the United States Veterans Affairs (VA) Healthcare System

Author

Zullig, Leah L., Jackson, George L., Dorn, Raye Anne, Provenzale, Dawn T., McNeil, Rebecca, Thomas, Catherine M., and Kelley, Michael J.

Subjects
Male, Lung Neoplasms, Skin Neoplasms, Incidence, Prostatic Neoplasms, Article, United States, United States Department of Veterans Affairs, Urinary Bladder Neoplasms, Neoplasms, Intestinal Neoplasms, Humans, Registries, Melanoma, Veterans
Abstract

Approximately 40,000 incident cancer cases are reported in the Veterans Affairs Central Cancer Registry (VACCR) annually (approximately 3% of U.S. cancer cases). Our objective was to provide the first comprehensive description of cancer incidence as reported in VACCR.Data were obtained from VACCR for incident cancers diagnosed in VA. Analyses focused on 2007 data. Cancer incidence among VA patients was compared to the general U.S. cancer population.In 2007, 97.5% of VA cancers were diagnosed among men. Approximately 78.5% of newly diagnosed patients were White, 19.0% Black, and 2.5% were another race. Median age at diagnosis was 66 years. The geographic distribution of cancer patients in VA aligns that of VA users. The most commonly diagnosed cancers were similar between VA and the U.S. male cancer population. The five most frequently diagnosed cancers among VA cancer patients were: prostate (31.8%), lung/bronchus (18.8%), colon/rectum (8.6%), urinary bladder (3.6%), and skin melanomas (3.4%). VA patients were diagnosed at an earlier stage of disease for the three most commonly diagnosed cancers--lung/bronchus, colon/rectum, and prostate--compared to the U.S. male cancer population.Registry data indicate that incident cancers in VA in 2007 approximately mirrored those observed among U.S. men.

Published
2012

217. Cancer Incidence Among Patients of the U.S. Veterans Affairs Health Care System

Author

Provenzale, Dawn T., Thomas, Catherine M., McNeil, Rebecca, Zullig, Leah L., Jackson, George L., Kelley, Michael J., and Dorn, Raye Anne

Abstract

Approximately 40,000 incident cancer cases are reported in VA Central Cancer Registry (VACCR) annually (~3% of United States cancer cases). Our objective was to provide the first comprehensive description of cancer incidence as reported in VACCR.

Published
2012
Full Text
View/download PDF

223. A Phase II Study of Dasatinib in Patients with Chemo-sensitive Relapsed Small Cell Lung Cancer (CALGB 30602)

Author

Miller, Antonius A., Pang, Herbert, Hodgson, Lydia, Ramnath, Nithya, Otterson, Gregory A., Kelley, Michael J., Kratzke, Robert A., and Vokes, Everett E.

Subjects
Adult, Aged, 80 and over, Male, Salvage Therapy, Lung Neoplasms, Dasatinib, Antineoplastic Agents, Middle Aged, Small Cell Lung Carcinoma, Article, Survival Rate, Thiazoles, Young Adult, Pyrimidines, Treatment Outcome, Drug Resistance, Neoplasm, Humans, Female, Neoplasm Recurrence, Local, Protein Kinase Inhibitors, Aged, Neoplasm Staging
Abstract

SRC is an oncogene with an essential role in the invasiveness and metastasis of solid tumors including small cell lung cancer. Dasatinib is a potent inhibitor of SRC as well as other tyrosine kinases. The primary objective of this study was to determine the efficacy of second-line dasatinib in patients with chemosensitive (relapse or progressionor =90 days after completing first-line therapy) small cell lung cancer.Patients with measurable disease; performance status 0 to 1; no more than one prior platinum-based chemotherapy regimen; and adequate hematologic, hepatic, and renal function were eligible. Dasatinib was administered orally at 70 mg twice daily continuously (1 cycle = 21 days) until disease progression or unacceptable toxicity. Response was determined after every two cycles. Patients were followed until disease progression or death. The study was prospectively designed to simultaneously discriminate between complete plus partial response rates of 5% versus 20% and progression-free survival (PFS) rates at 6 weeks of 50% versus 70.7% in 53 evaluable patients with at least 92% power. The study was to be terminated early and declared negative if 1 or less objective response and 14 or fewer instances of PFSor =6 weeks were observed among the initial 27 patients; however, patient accrual continued while the initial 27 patients were evaluated.Between April 2007 and December 2008, 45 patients were enrolled, but one patient never received any protocol therapy and one patient was ineligible: male/female, 17/26; white/black/unknown, 40/2/1; median age, 64 years (range, 35-84 years); and performance status 0/1, 12/31. No objective response was recorded among the 43 eligible and treated patients. Among the initial 27 patients, only 13 instances of PFSor =6 weeks were observed. With a median follow-up time of 7.1 months, median estimated overall survival and PFS times for the 43 eligible and treated patients were 17.0 and 5.9 weeks, respectively. Common reasons for removal of patients from protocol treatment were progressive disease (65%) and adverse events (26%). Toxicity was generally mild to moderate: grade 3 events of5% frequency included fatigue and pleural and pericardial effusions; and no grade 4 or 5 events were encountered.Dasatinib did not reach our specified efficacy criteria in this clinical setting, and the study was terminated.

Published
2010

224. Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non–Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data

Author

Santana-Davila, Rafael, primary, Devisetty, Kiran, additional, Szabo, Aniko, additional, Sparapani, Rodney, additional, Arce-Lara, Carlos, additional, Gore, Elizabeth M., additional, Moran, Amy, additional, Williams, Christina D., additional, Kelley, Michael J., additional, and Whittle, Jeffrey, additional

Published
2015
Full Text
View/download PDF

226. Cancer Incidence in HIV-Infected Versus Uninfected Veterans: Comparison of Cancer Registry and ICD-9 Code Diagnoses.

Author

Park, Lesley S, Park, Lesley S, Tate, Janet P, Rodriguez-Barradas, Maria C, Rimland, David, Goetz, Matthew Bidwell, Gibert, Cynthia, Brown, Sheldon T, Kelley, Michael J, Justice, Amy C, Dubrow, Robert, Park, Lesley S, Park, Lesley S, Tate, Janet P, Rodriguez-Barradas, Maria C, Rimland, David, Goetz, Matthew Bidwell, Gibert, Cynthia, Brown, Sheldon T, Kelley, Michael J, Justice, Amy C, and Dubrow, Robert

Abstract

BackgroundGiven the growing interest in the cancer burden in persons living with HIV/AIDS, we examined the validity of data sources for cancer diagnoses (cancer registry versus International Classification of Diseases, Ninth Revision [ICD-9 codes]) and compared the association between HIV status and cancer risk using each data source in the Veterans Aging Cohort Study (VACS), a prospective cohort of HIV-infected and uninfected veterans from 1996 to 2008.MethodsWe reviewed charts to confirm potential incident cancers at four VACS sites. In the entire cohort, we calculated cancer-type-specific age-, sex-, race/ethnicity-, and calendar-period-standardized incidence rates and incidence rate ratios (IRR) (HIV-infected versus uninfected). We calculated standardized incidence ratios (SIR) to compare VACS and Surveillance, Epidemiology, and End Results rates.ResultsCompared to chart review, both Veterans Affairs Central Cancer Registry (VACCR) and ICD-9 diagnoses had approximately 90% sensitivity; however, VACCR had higher positive predictive value (96% versus 63%). There were 6,010 VACCR and 13,386 ICD-9 incident cancers among 116,072 veterans. Although ICD-9 rates tended to be double VACCR rates, most IRRs were in the same direction and of similar magnitude, regardless of data source. Using either source, all cancers combined, most viral-infection-related cancers, lung cancer, melanoma, and leukemia had significantly elevated IRRs. Using ICD-9, eight additional IRRs were significantly elevated, most likely due to false positive diagnoses. Most ICD-9 SIRs were significantly elevated and all were higher than the corresponding VACCR SIR.ConclusionsICD-9 may be used with caution for estimating IRRs, but should be avoided when estimating incidence or SIRs. Elevated cancer risk based on VACCR diagnoses among HIV-infected veterans was consistent with other studies.

Published
2014

228. Reply to B.L. King-Kallimanis et al.

Author

Friedman, Daphne R., Halwani, Ahmad S., and Kelley, Michael J.

Subjects
ELECTRONIC health records
Abstract

We thank King-Kallimanis et al[1] for their comments regarding our recent publication[2] and for providing the opportunity to clarify some points about the Veteran Symptom Assessment System (VSAS). JCO Clin Cancer Inform; 6: e2100086, 2022 3 Zullig LL, Sims KJ, McNeil R, et al: Cancer incidence among patients of the U.S. Veterans Affairs Health Care System: 2010 update. As noted by King-Kallimanis et al,[1] the median time between cancer diagnosis and initial VSAS measurement shortens with each year of implementation, which is a type of chronological bias inherent in implementation projects. [Extracted from the article]

Published
2022
Full Text
View/download PDF

231. Implementation of Lung Cancer Screening in the Veterans Health Administration.

Author

Kinsinger, Linda S., Anderson, Charles, Kim, Jane, Larson, Martha, Chan, Stephanie H., King, Heather A., Rice, Kathryn L., Slatore, Christopher G., Tanner, Nichole T., Pittman, Kathleen, Monte, Robert J., McNeil, Rebecca B., Grubber, Janet M., Kelley, Michael J., Provenzale, Dawn, Datta, Santanu K., Sperber, Nina S., Barnes, Lottie K., Abbott, David H., and Sims, Kellie J.

Published
2017
Full Text
View/download PDF

232. Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Author

Kelley, Michael J., Jha, Gautam, Shoemaker, Debra, Herndon II, James E., Gu, Lin, Barry, William T., Crawford, Jeffrey, and Ready, Neal

Subjects
*CANCER treatment, *DASATINIB, *NON-small-cell lung carcinoma, *PNEUMOTHORAX, *BIOMARKERS, *PATIENTS, *THERAPEUTICS
Abstract

The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients had minor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

241. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

Author

Patel, Jai N., primary, Jiang, Chen, additional, Hertz, Daniel L., additional, Mulkey, Flora A., additional, Owzar, Kouros, additional, Halabi, Susan, additional, Ratain, Mark J., additional, Friedman, Paula N., additional, Small, Eric J., additional, Carducci, Michael A., additional, Mahoney, John F., additional, Kelley, Michael J., additional, Morris, Michael J., additional, Kelly, William K., additional, and McLeod, Howard L., additional

Published
2014
Full Text
View/download PDF

242. Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines

Author

Karikari, Isaac O., primary, Gilchrist, Christopher L., additional, Jing, Liufang, additional, Alcorta, David A., additional, Chen, Jun, additional, Richardson, William J., additional, Gabr, Mostafa A., additional, Bell, Richard D., additional, Kelley, Michael J., additional, Bagley, Carlos A., additional, and Setton, Lori A., additional

Published
2014
Full Text
View/download PDF

245. Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma

Author

Kelley, Michael J., primary, Shi, Jianxin, additional, Ballew, Bari, additional, Hyland, Paula L., additional, Li, Wen-Qing, additional, Rotunno, Melissa, additional, Alcorta, David A., additional, Liebsch, Norbert J., additional, Mitchell, Jason, additional, Bass, Sara, additional, Roberson, David, additional, Boland, Joseph, additional, Cullen, Michael, additional, He, Ji, additional, Burdette, Laurie, additional, Yeager, Meredith, additional, Chanock, Stephen J., additional, Parry, Dilys M., additional, Goldstein, Alisa M., additional, and Yang, Xiaohong R., additional

Published
2014
Full Text
View/download PDF

246. A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).

Author

Hertz, Daniel Louis, primary, Jiang, Chen, additional, Owzar, Kouros, additional, Halabi, Susan, additional, Kelly, William Kevin, additional, Mulkey, Flora, additional, Patel, Jai Narendra, additional, Carducci, Michael Anthony, additional, Kelley, Michael J., additional, Stadler, Walter Michael, additional, Mohamed, Mohamed K., additional, Morris, Michael J., additional, Nakamura, Yusuke, additional, Zembutsu, Hitoshi, additional, Ratain, Mark J., additional, and McLeod, Howard L., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results